Association among Soluble Tumor Necrosis Factor Receptor I, Matrix Metalloproteinase-9, Procollagen C-terminal Propeptide type I, and N-Terminal proBrain Natriuretic Peptide in Heart Failure

Mona Yolanda, Marsetio Donosepoetro, Anwar Santoso, Mansyur Arif

Abstract


BACKGROUND: Heart failure (HF) is associated with an increased expression of proinflammatory cytokines, especially soluble tumor necrosis factor receptor I (sTNFR I), but the underlying mechanism to the relationship between sTNFR I activation and the progression of HF is not yet fully understood. This study aims to see the association between sTNFR I, MMP-9, PICP, and NT-proBNP in the progression of HF.

METHODS: This was a cross sectional study which recruited 45 subjects with HF confirmed by echocardiography and NT-proBNP. Concentration sTNFR I, MMP-9, and PICP were measured using ELISA method, whereas NT-proBNP concentration was measured using ECLIA method. Univariate linear regression analysis, path analysis and General Linear Model were used to determine which parameters played the most significant role in HF.

RESULTS: Results of the univariate linear regression and path analysis showed there was a linear relationship between sTNFR I with MMP-9, with R square of 25.8% (p=0.00; r=0.508), R square sTNFRI and MMP-9 with PICP was 14.4% (p=0.038; r=0.379) and R square MMP-9 and PICP with NT-proBNP was 39.6% (p=0.00; r=0.629). From the General Linear Model we found that the important predictor for HF was through MMP-9 and PICP.

CONCLUSION: sTNFR I as a proinflammatory factor is one of the factors involved in the heart failure as seen by NT-proBNP through activation of brosis (PICP) and remodeling factor (MMP-9).

KEYWORDS: sTNFR I, MMP-9, PICP, NT-proBNP, heart failure


Full Text:

PDF

References


Mair J. Pathophysiology of heart failure. In: Wu AHB, editor. Cardiac Markers, Part of the series Pathology and Laboratory Medicine. Totowa, New Jersey: Humana Press; 2003. p.351-67, CrossRef.

Murray DR, Freeman GL. Proinflammatory cytokines: predictors of a failing heart? Circulation. 2003; 107: 1460-2, CrossRef.

Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res. 2003; 92: 827-39, CrossRef.

Cuspidi C, Ciulla M, Zanchetti A. Hypertensive myocardial fibrosis. Nephrol Dial Transplant. 2006; 21: 20-3, CrossRef.

Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TD, et al. 2009 focused update : ACC/AHA guidelines for the diagnosis and management of heart failure in adults. Circulation. 2009; 119: 1977-2016, CrossRef.

Braunwald E. Biomarkers in heart failure. N Engl J Med. 2008; 358: 2148-59, CrossRef.

Deschamps AM, Spinale FG. Extracellular matrix. In: Walsh RA, editor. Molecular Mechanism of Cardiac Hypertrophy and Failure. [n.p]: CRC Press; 2005. p.125-46, CrossRef.

Spinale FG, Coker ML, Heung LJ, Bond BR, Gunasinghe HR, Etoh T, et al. A matrix metalloproteinase induction/activation system exists the human left ventricular myocardium and is upregulated in heart failure. Circulation. 2000; 102: 1944-9, CrossRef.

Garcia-Bolao I, Lopez B, Macias A, Gavira JJ, Azcarate P, Diez J. Impact of collagen type I turnover on the long-term response to cardiac resynchronization therapy. Eur Heart J. 2008; 29: 898-906, CrossRef.

Deschamps AM, Spinale FG. Pathways of matrix metalloproteinase induction in heart failure: Bioactive molecules and transcriptional regulation. Cardiovasc Res. 2006; 69: 666-76, CrossRef.

Lopez B, Gonzalez A, Diez J. Circulating biomarkers of collagen metabolism in cardiac disease. Circulation. 2010; 121: 1645-54, CrossRef.

Zannad F, Alla F, Dousset B, Perez A, Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure : insights from the randomized aldactone evaluation study (RALES). Circulation. 2000; 102: 2700-6, CrossRef.

Hansson J, Lind L, Hulthe J, Sundström J. Relations of serum MMP-9 and TIMP-1 levels to left ventricular measures and cardiovascular risk factors: a population-based study. Eur J Cardiovasc Prev Rehabil. 2009; 16: 297-303, CrossRef.

Polyakova V, Hein S, Kostin S, Ziegelhoeffer T, Schaper J. Matrix metalloproteinases and their tissue inhibitors in pressure-overloaded human myocardium during heart failure progression. J Am Coll Cardiol. 2004; 44: 1609-18, CrossRef.

Li Y. Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling. Cardiovasc Res. 2000; 46: 214-24, CrossRef.




DOI: https://doi.org/10.18585/inabj.v3i1.136

Indexed by:

                 

                  

               

     

 

The Prodia Education and Research Institute